Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025Frontiers in ImmunologyOpen Access

Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

RXRongxia XieKZKefeng ZhaiJYJinming Yu

Discussion

Loading...

Member takes

Overview

Observational analysis identifies low expression of immunoproteasome subunits predicting MPR in NSCLC, suggesting new prognostic biomarkers.

Key Points

  • Low pre-treatment expression of LMP2, PSME1, and PSME2 significantly predicts major pathologic response in resectable NSCLC.
  • Clinical findings indicate that high LMP2 expression correlates with significantly improved overall survival in NSCLC patients receiving neoadjuvant therapy.
  • Bioinformatic analysis confirmed LMP2, PSME1, and PSME2 as vital for antigen presentation pathways in predicting treatment response.
  • Multivariate analysis established MPR status and high LMP2 as independent prognostic factors for overall survival in patients treated with neoadjuvant chemoimmunotherapy.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68d45e6231b076d99fa5ec5bhttps://doi.org/10.3389/fimmu.2025.1654573
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC2025
  2. 2High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)2024 · 8 citations
  3. 3Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer2024 · 9 citations
  4. 4Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer.2024
  5. 5Prognostic analysis of immunomarkers for non-small cell lung cancer2025